Emerging roles of long noncoding RNA H19 in human lung cancer

Lung cancer holds the position of being the primary cause of cancer‐related fatalities on a global scale. Furthermore, it exhibits the highest mortality rate among all types of cancer. The survival rate within a span of 5 years is less than 20%, primarily due to the fact that the disease is often di...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell biochemistry and function Ročník 42; číslo 4; s. e4072 - n/a
Hlavní autoři: Ahmad, Irfan, Jasim, Saade Abdalkareem, Sergeevna, Klunko Nataliya, Jyothi.S, Renuka, Kumar, Ashwani, Dusanov, Abdigafur, Shuhata Alubiady, Mahmood Hasen, Sinha, Aashna, Zain Al‐Abdeen, Salah Hassan, Hjazi, Ahmed
Médium: Journal Article
Jazyk:angličtina
Vydáno: England Wiley Subscription Services, Inc 01.06.2024
Témata:
Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Cell migration
Disease resistance
EMT
Epithelial-Mesenchymal Transition
Gene Expression Regulation, Neoplastic
Humans
lncRNA H19
Lung cancer
Lung diseases
Lung Neoplasms - diagnosis
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Metastases
metastasis
Molecular modelling
Non-coding RNA
RNA, Long Noncoding - genetics
RNA, Long Noncoding - metabolism
Survival
therapy resistance
Tumorigenesis
lncRNA H19
lung cancer
metastasis
EMT
therapy resistance
ISSN:0263-6484, 1099-0844, 1099-0844
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Lung cancer holds the position of being the primary cause of cancer‐related fatalities on a global scale. Furthermore, it exhibits the highest mortality rate among all types of cancer. The survival rate within a span of 5 years is less than 20%, primarily due to the fact that the disease is often diagnosed at an advanced stage, resulting in less effective treatment options compared to earlier stages. There are two main types of primary lung cancer: nonsmall‐cell lung cancer, which accounts for approximately 80%–85% of all cases, and small‐cell lung cancer, which is categorized based on the specific type of cells in which the cancer originates. The understanding of the biology of this disease and the identification of oncogenic driver alterations have significantly transformed the landscape of therapeutic approaches. Long noncoding RNAs (lncRNAs) play a crucial role in regulating various physiological and pathological processes through diverse molecular mechanisms. Among these lncRNAs, lncRNA H19, initially identified as an oncofetal transcript, has garnered significant attention due to its elevated expression in numerous tumors. Extensive research has confirmed its involvement in tumorigenesis and malignant progression by promoting cell growth, invasion, migration, epithelial‐mesenchymal transition, metastasis, and therapy resistance. This comprehensive review aims to provide an overview of the aberrant overexpression of lncRNA H19 and the molecular pathways through which it contributes to the advancement of lung cancer. The findings of this review highlight the potential for further investigation into the diagnosis and treatment of this disease, offering promising avenues for future research. Significance Statement Since today the role of different long noncoding RNAs (lncRNAs) in the development of various cancers has been determined to some extent, our aim is to investigate the role of lncRNA H19 in the progression of lung cancer. It is hoped that with a comprehensive review of past studies, this lncRNA can be used as a target for identifying and treating this cancer.
AbstractList Lung cancer holds the position of being the primary cause of cancer-related fatalities on a global scale. Furthermore, it exhibits the highest mortality rate among all types of cancer. The survival rate within a span of 5 years is less than 20%, primarily due to the fact that the disease is often diagnosed at an advanced stage, resulting in less effective treatment options compared to earlier stages. There are two main types of primary lung cancer: nonsmall-cell lung cancer, which accounts for approximately 80%-85% of all cases, and small-cell lung cancer, which is categorized based on the specific type of cells in which the cancer originates. The understanding of the biology of this disease and the identification of oncogenic driver alterations have significantly transformed the landscape of therapeutic approaches. Long noncoding RNAs (lncRNAs) play a crucial role in regulating various physiological and pathological processes through diverse molecular mechanisms. Among these lncRNAs, lncRNA H19, initially identified as an oncofetal transcript, has garnered significant attention due to its elevated expression in numerous tumors. Extensive research has confirmed its involvement in tumorigenesis and malignant progression by promoting cell growth, invasion, migration, epithelial-mesenchymal transition, metastasis, and therapy resistance. This comprehensive review aims to provide an overview of the aberrant overexpression of lncRNA H19 and the molecular pathways through which it contributes to the advancement of lung cancer. The findings of this review highlight the potential for further investigation into the diagnosis and treatment of this disease, offering promising avenues for future research.Lung cancer holds the position of being the primary cause of cancer-related fatalities on a global scale. Furthermore, it exhibits the highest mortality rate among all types of cancer. The survival rate within a span of 5 years is less than 20%, primarily due to the fact that the disease is often diagnosed at an advanced stage, resulting in less effective treatment options compared to earlier stages. There are two main types of primary lung cancer: nonsmall-cell lung cancer, which accounts for approximately 80%-85% of all cases, and small-cell lung cancer, which is categorized based on the specific type of cells in which the cancer originates. The understanding of the biology of this disease and the identification of oncogenic driver alterations have significantly transformed the landscape of therapeutic approaches. Long noncoding RNAs (lncRNAs) play a crucial role in regulating various physiological and pathological processes through diverse molecular mechanisms. Among these lncRNAs, lncRNA H19, initially identified as an oncofetal transcript, has garnered significant attention due to its elevated expression in numerous tumors. Extensive research has confirmed its involvement in tumorigenesis and malignant progression by promoting cell growth, invasion, migration, epithelial-mesenchymal transition, metastasis, and therapy resistance. This comprehensive review aims to provide an overview of the aberrant overexpression of lncRNA H19 and the molecular pathways through which it contributes to the advancement of lung cancer. The findings of this review highlight the potential for further investigation into the diagnosis and treatment of this disease, offering promising avenues for future research.
Lung cancer holds the position of being the primary cause of cancer‐related fatalities on a global scale. Furthermore, it exhibits the highest mortality rate among all types of cancer. The survival rate within a span of 5 years is less than 20%, primarily due to the fact that the disease is often diagnosed at an advanced stage, resulting in less effective treatment options compared to earlier stages. There are two main types of primary lung cancer: nonsmall‐cell lung cancer, which accounts for approximately 80%–85% of all cases, and small‐cell lung cancer, which is categorized based on the specific type of cells in which the cancer originates. The understanding of the biology of this disease and the identification of oncogenic driver alterations have significantly transformed the landscape of therapeutic approaches. Long noncoding RNAs (lncRNAs) play a crucial role in regulating various physiological and pathological processes through diverse molecular mechanisms. Among these lncRNAs, lncRNA H19, initially identified as an oncofetal transcript, has garnered significant attention due to its elevated expression in numerous tumors. Extensive research has confirmed its involvement in tumorigenesis and malignant progression by promoting cell growth, invasion, migration, epithelial‐mesenchymal transition, metastasis, and therapy resistance. This comprehensive review aims to provide an overview of the aberrant overexpression of lncRNA H19 and the molecular pathways through which it contributes to the advancement of lung cancer. The findings of this review highlight the potential for further investigation into the diagnosis and treatment of this disease, offering promising avenues for future research. Significance Statement Since today the role of different long noncoding RNAs (lncRNAs) in the development of various cancers has been determined to some extent, our aim is to investigate the role of lncRNA H19 in the progression of lung cancer. It is hoped that with a comprehensive review of past studies, this lncRNA can be used as a target for identifying and treating this cancer.
Lung cancer holds the position of being the primary cause of cancer‐related fatalities on a global scale. Furthermore, it exhibits the highest mortality rate among all types of cancer. The survival rate within a span of 5 years is less than 20%, primarily due to the fact that the disease is often diagnosed at an advanced stage, resulting in less effective treatment options compared to earlier stages. There are two main types of primary lung cancer: nonsmall‐cell lung cancer, which accounts for approximately 80%–85% of all cases, and small‐cell lung cancer, which is categorized based on the specific type of cells in which the cancer originates. The understanding of the biology of this disease and the identification of oncogenic driver alterations have significantly transformed the landscape of therapeutic approaches. Long noncoding RNAs (lncRNAs) play a crucial role in regulating various physiological and pathological processes through diverse molecular mechanisms. Among these lncRNAs, lncRNA H19, initially identified as an oncofetal transcript, has garnered significant attention due to its elevated expression in numerous tumors. Extensive research has confirmed its involvement in tumorigenesis and malignant progression by promoting cell growth, invasion, migration, epithelial‐mesenchymal transition, metastasis, and therapy resistance. This comprehensive review aims to provide an overview of the aberrant overexpression of lncRNA H19 and the molecular pathways through which it contributes to the advancement of lung cancer. The findings of this review highlight the potential for further investigation into the diagnosis and treatment of this disease, offering promising avenues for future research. Since today the role of different long noncoding RNAs (lncRNAs) in the development of various cancers has been determined to some extent, our aim is to investigate the role of lncRNA H19 in the progression of lung cancer. It is hoped that with a comprehensive review of past studies, this lncRNA can be used as a target for identifying and treating this cancer.
Lung cancer holds the position of being the primary cause of cancer-related fatalities on a global scale. Furthermore, it exhibits the highest mortality rate among all types of cancer. The survival rate within a span of 5 years is less than 20%, primarily due to the fact that the disease is often diagnosed at an advanced stage, resulting in less effective treatment options compared to earlier stages. There are two main types of primary lung cancer: nonsmall-cell lung cancer, which accounts for approximately 80%-85% of all cases, and small-cell lung cancer, which is categorized based on the specific type of cells in which the cancer originates. The understanding of the biology of this disease and the identification of oncogenic driver alterations have significantly transformed the landscape of therapeutic approaches. Long noncoding RNAs (lncRNAs) play a crucial role in regulating various physiological and pathological processes through diverse molecular mechanisms. Among these lncRNAs, lncRNA H19, initially identified as an oncofetal transcript, has garnered significant attention due to its elevated expression in numerous tumors. Extensive research has confirmed its involvement in tumorigenesis and malignant progression by promoting cell growth, invasion, migration, epithelial-mesenchymal transition, metastasis, and therapy resistance. This comprehensive review aims to provide an overview of the aberrant overexpression of lncRNA H19 and the molecular pathways through which it contributes to the advancement of lung cancer. The findings of this review highlight the potential for further investigation into the diagnosis and treatment of this disease, offering promising avenues for future research.
Author Jasim, Saade Abdalkareem
Jyothi.S, Renuka
Kumar, Ashwani
Hjazi, Ahmed
Zain Al‐Abdeen, Salah Hassan
Dusanov, Abdigafur
Sergeevna, Klunko Nataliya
Ahmad, Irfan
Sinha, Aashna
Shuhata Alubiady, Mahmood Hasen
Author_xml – sequence: 1
  givenname: Irfan
  surname: Ahmad
  fullname: Ahmad, Irfan
  organization: King Khalid University
– sequence: 2
  givenname: Saade Abdalkareem
  orcidid: 0009-0001-3559-860X
  surname: Jasim
  fullname: Jasim, Saade Abdalkareem
  email: s65423100@gmail.com, saade.a.j@uoa.edu.iq
  organization: Al‐maarif University College
– sequence: 3
  givenname: Klunko Nataliya
  surname: Sergeevna
  fullname: Sergeevna, Klunko Nataliya
  organization: Russian New University
– sequence: 4
  givenname: Renuka
  surname: Jyothi.S
  fullname: Jyothi.S, Renuka
  organization: JAIN (Deemed to be University)
– sequence: 5
  givenname: Ashwani
  surname: Kumar
  fullname: Kumar, Ashwani
  organization: Vivekananda Global University
– sequence: 6
  givenname: Abdigafur
  surname: Dusanov
  fullname: Dusanov, Abdigafur
  organization: Samarkand State Medical University
– sequence: 7
  givenname: Mahmood Hasen
  surname: Shuhata Alubiady
  fullname: Shuhata Alubiady, Mahmood Hasen
  organization: Al‐Hadi University College
– sequence: 8
  givenname: Aashna
  surname: Sinha
  fullname: Sinha, Aashna
  organization: Uttaranchal University
– sequence: 9
  givenname: Salah Hassan
  surname: Zain Al‐Abdeen
  fullname: Zain Al‐Abdeen, Salah Hassan
  organization: AL‐Nisour University College
– sequence: 10
  givenname: Ahmed
  surname: Hjazi
  fullname: Hjazi, Ahmed
  organization: Prince Sattam bin Abdulaziz University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39031589$$D View this record in MEDLINE/PubMed
BookMark eNp1kEtLAzEUhYMotlXBXyADbtxMvXk0j4ULLdUKoiC6HtI00SkziSYdpP_eVKuC6OpyD98593IGaNsHbxE6xDDEAOTUzNyQgSBbqI9BqRIkY9uoD4TTkjPJemiQ0gIAFKewi3pUAcUjqfrobNLa-FT7pyKGxqYiuKIJecsHTJiv9fvb82KKVVH74rlrtS-aLqtGe2PjPtpxukn2YDP30OPl5GE8LW_urq7H5zeloUyRciaxlsIKowSfCSl5FggGY8BJTph1mmNqHNHGUCyZ5lY4RtWcO2yUYUD30Mln7ksMr51Ny6qtk7FNo70NXaooSKJGEhTL6PEvdBG66PN3mRKECoH5KFNHG6qbtXZevcS61XFVfRXzc9HEkFK07hvBUK07r3Ln1brzjA5_oaZe6mUd_DLquvnLUH4a3urGrv4NrsYXlx_8O_EDjYU
CitedBy_id crossref_primary_10_1038_s41598_025_12522_5
crossref_primary_10_1016_j_jep_2025_119555
Cites_doi 10.1186/s12943-019-1091-2
10.1016/j.bioactmat.2021.11.013
10.1038/nrc2584
10.3390/ncrna9050058
10.1097/MD.0000000000032899
10.2147/OTT.S167853
10.1172/JCI159839
10.1007/s11356-021-14550-w
10.1159/000430309
10.1016/j.canlet.2020.05.009
10.1016/j.prp.2021.153432
10.1016/j.canlet.2021.04.002
10.1016/S1535-6108(02)00027-2
10.3390/ijms23158309
10.1159/000518627
10.3390/ijms242216484
10.1016/j.tcb.2018.12.001
10.7150/thno.25541
10.3390/ijms20112767
10.3389/fgene.2022.1005522
10.1038/s41418-018-0246-9
10.18632/oncotarget.6387
10.1002/jcp.26530
10.1016/j.biopha.2019.109774
10.2147/CMAR.S241095
10.1186/s10020-020-00156-4
10.1080/01902148.2016.1223229
10.1016/j.ymthe.2019.09.001
10.3390/cancers14184486
10.1111/jcmm.14533
10.1002/cac2.12108
10.1007/s13277-015-4347-5
10.1007/s13277-015-4185-5
10.3892/ijo.2017.3941
10.2217/pme-2023-0081
10.18632/oncotarget.4154
10.1002/jcb.29182
10.2147/OTT.S185156
10.1186/s13046-020-01690-z
10.1002/jcp.31076
10.1200/JCO.18.01585
10.1016/j.path.2019.11.002
10.1126/science.abg5601
10.1101/gad.234294.113
10.1186/s12943-015-0458-2
10.1042/EBC20200032
10.1007/s11033-020-05695-x
10.1016/j.biopha.2020.110909
10.1186/s12935-022-02736-2
10.1242/dmm.047662
10.1111/jcmm.15245
10.18632/oncotarget.13708
10.1097/MD.0000000000030045
10.1016/j.biopha.2023.115242
10.1016/j.cllc.2022.11.005
10.21037/tcr-22-1812
10.1186/s12885-018-4795-6
10.1080/15384101.2018.1482137
10.1186/s12881-018-0573-1
10.4103/jcrt.JCRT_733_17
10.1111/j.1742-4658.2012.08694.x
10.1002/jcla.23311
10.1016/j.canlet.2020.11.006
10.1186/s12935-021-02268-1
10.18632/oncotarget.8330
10.1101/gad.234419.113
10.1074/jbc.M504033200
10.1016/j.phrs.2022.106418
10.3390/ijms18020450
10.3892/ijo.2021.5270
10.1097/CAD.0000000000000831
10.3390/cells10071715
10.3390/ijms24098178
10.1016/j.trecan.2020.06.005
10.2147/OTT.S245710
10.1007/s11033-021-06603-7
10.1016/j.lfs.2023.121997
10.1007/s11010-019-03564-1
10.1186/s12943-018-0777-1
10.1093/oxfordjournals.jbchem.a022661
10.1016/j.phrs.2023.106739
10.1002/cac2.12359
10.3322/caac.21660
10.1038/cgt.2017.20
ContentType Journal Article
Copyright 2024 John Wiley & Sons Ltd.
Copyright_xml – notice: 2024 John Wiley & Sons Ltd.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
7TM
7U7
8FD
C1K
FR3
P64
RC3
7X8
DOI 10.1002/cbf.4072
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Neurosciences Abstracts
Nucleic Acids Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Technology Research Database
Toxicology Abstracts
Nucleic Acids Abstracts
Chemoreception Abstracts
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

CrossRef
MEDLINE
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Biology
EISSN 1099-0844
EndPage n/a
ExternalDocumentID 39031589
10_1002_cbf_4072
CBF4072
Genre reviewArticle
Journal Article
Review
GrantInformation_xml – fundername: Deanship of Scientific Research at King Khalid University
  funderid: RGP.02/42/45
– fundername: Deanship of Scientific Research at King Khalid University
  grantid: RGP.02/42/45
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
1ZS
29B
31~
33P
3SF
3WU
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
6J9
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACIWK
ACMXC
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BLYAC
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR1
DR2
DRFUL
DRMAN
DRSTM
DU5
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GNP
GODZA
H.X
HF~
HGLYW
HHY
HHZ
HVGLF
HZ~
IX1
J0M
JPC
KBYEO
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LH6
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NDZJH
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
Q.N
Q11
QB0
QRW
R.K
RBB
RIWAO
RJQFR
ROL
RWI
RX1
RYL
SAMSI
SUPJJ
SV3
TEORI
UB1
V2E
V8K
W8V
W99
WBKPD
WH7
WIB
WIH
WIJ
WIK
WJL
WNSPC
WOHZO
WQJ
WRC
WSB
WXI
WXSBR
WYISQ
XG1
XPP
XV2
ZZTAW
~IA
~WT
AAMMB
AAYXX
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
AIQQE
CITATION
O8X
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7QR
7TK
7TM
7U7
8FD
C1K
FR3
P64
RC3
7X8
ID FETCH-LOGICAL-c3492-b81a87e7c976b7886b81210cc0f8624efa613cf2acc3184a6e7f439d6f1c9c403
IEDL.DBID DRFUL
ISICitedReferencesCount 3
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001251336200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0263-6484
1099-0844
IngestDate Thu Oct 02 11:55:47 EDT 2025
Thu Oct 16 00:40:27 EDT 2025
Wed Feb 19 02:07:43 EST 2025
Sat Nov 29 07:15:13 EST 2025
Tue Nov 18 22:18:30 EST 2025
Wed Jan 22 17:18:11 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords lncRNA H19
lung cancer
metastasis
EMT
therapy resistance
Language English
License 2024 John Wiley & Sons Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3492-b81a87e7c976b7886b81210cc0f8624efa613cf2acc3184a6e7f439d6f1c9c403
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0009-0001-3559-860X
PMID 39031589
PQID 3072377165
PQPubID 2029981
PageCount 10
ParticipantIDs proquest_miscellaneous_3082958094
proquest_journals_3072377165
pubmed_primary_39031589
crossref_primary_10_1002_cbf_4072
crossref_citationtrail_10_1002_cbf_4072
wiley_primary_10_1002_cbf_4072_CBF4072
PublicationCentury 2000
PublicationDate June 2024
2024-06-00
2024-Jun
20240601
PublicationDateYYYYMMDD 2024-06-01
PublicationDate_xml – month: 06
  year: 2024
  text: June 2024
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Bognor Regis
PublicationTitle Cell biochemistry and function
PublicationTitleAlternate Cell Biochem Funct
PublicationYear 2024
Publisher Wiley Subscription Services, Inc
Publisher_xml – name: Wiley Subscription Services, Inc
References 2022; 376
2022; 132
2015; 36
2019; 2019
2017; 8
2021; 65
2021; 21
2023; 102
2023; 9
2021; 28
2019; 12
2022; 23
2019; 18
2020; 13
2020; 486
2023; 1
2020; 123
2020; 12
2018; 40
2022; 22
2014; 28
2021; 71
2016; 37
2019; 120
2023; 20
2020; 6
2018; 8
2023; 24
2019; 20
2000; 127
2022; 40
2019; 23
2019; 26
2023; 330
2019; 27
2016; 42
2020; 47
2019; 29
2021; 41
2021; 48
2015; 14
2019; 9
2015; 6
2021; 509
2021; 222
2021; 500
2023; 15
2019; 37
2017; 24
2023; 165
2002; 1
2020; 39
2020; 34
2022; 42
2019; 460
2018; 22
2021; 14
2022; 101
2017; 50
2018; 19
2005; 280
2018; 18
2016; 7
2018; 17
2021; 59
2021; 10
2022; 184
2023; 191
2020; 31
2018; 233
2017; 10
2023; 238
2022; 13
2009; 9
2020; 26
2022; 14
2020; 24
2017; 18
2021; 133
2022; 11
2012; 279
2018; 11
2018; 14
e_1_2_8_28_1
e_1_2_8_24_1
e_1_2_8_47_1
e_1_2_8_26_1
e_1_2_8_49_1
e_1_2_8_3_1
e_1_2_8_81_1
e_1_2_8_5_1
e_1_2_8_7_1
Qian B (e_1_2_8_73_1) 2018; 22
e_1_2_8_9_1
e_1_2_8_20_1
e_1_2_8_43_1
e_1_2_8_66_1
e_1_2_8_89_1
e_1_2_8_22_1
e_1_2_8_45_1
e_1_2_8_64_1
e_1_2_8_87_1
e_1_2_8_85_1
e_1_2_8_41_1
e_1_2_8_60_1
e_1_2_8_83_1
e_1_2_8_17_1
Xu JL (e_1_2_8_63_1) 2019; 23
e_1_2_8_19_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_59_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_57_1
Huang T (e_1_2_8_68_1) 2017; 10
Jonna S (e_1_2_8_4_1) 2019; 27
e_1_2_8_70_1
e_1_2_8_91_1
e_1_2_8_32_1
e_1_2_8_55_1
e_1_2_8_78_1
e_1_2_8_11_1
e_1_2_8_34_1
e_1_2_8_53_1
e_1_2_8_76_1
e_1_2_8_51_1
e_1_2_8_74_1
e_1_2_8_30_1
e_1_2_8_72_1
e_1_2_8_93_1
e_1_2_8_29_1
e_1_2_8_25_1
e_1_2_8_46_1
e_1_2_8_27_1
e_1_2_8_48_1
e_1_2_8_69_1
Gu B (e_1_2_8_62_1) 2023; 15
e_1_2_8_2_1
e_1_2_8_80_1
e_1_2_8_6_1
e_1_2_8_8_1
e_1_2_8_42_1
e_1_2_8_67_1
e_1_2_8_88_1
e_1_2_8_23_1
e_1_2_8_44_1
e_1_2_8_65_1
e_1_2_8_86_1
Liu Y (e_1_2_8_50_1) 2019; 2019
e_1_2_8_84_1
e_1_2_8_40_1
e_1_2_8_61_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_16_1
e_1_2_8_37_1
e_1_2_8_58_1
e_1_2_8_79_1
Lei Y (e_1_2_8_82_1) 2018; 40
Kong BY (e_1_2_8_92_1) 2019; 9
e_1_2_8_94_1
e_1_2_8_90_1
Mehmandar‐Oskuie A (e_1_2_8_21_1) 2023; 1
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_56_1
e_1_2_8_77_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_54_1
e_1_2_8_75_1
e_1_2_8_52_1
e_1_2_8_71_1
References_xml – volume: 8
  start-page: 2558
  issue: 2
  year: 2017
  end-page: 2567
  article-title: Correlation of long non‐coding RNA H19 expression with cisplatin‐resistance and clinical outcome in lung adenocarcinoma
  publication-title: Oncotarget
– volume: 26
  start-page: 199
  issue: 2
  year: 2019
  end-page: 212
  article-title: Mutant p53 as a guardian of the cancer cell
  publication-title: Cell Death Differ
– volume: 24
  start-page: 114
  issue: 2
  year: 2023
  end-page: 119
  article-title: Trends in stage I lung cancer
  publication-title: Clin Lung Cancer
– volume: 13
  start-page: 3525
  year: 2020
  end-page: 3534
  article-title: Long noncoding RNA H19 facilitates small cell lung cancer tumorigenesis through miR‐140‐5p/FGF9 axis
  publication-title: Onco Targets Ther
– volume: 486
  start-page: 58
  year: 2020
  end-page: 70
  article-title: LncRNA H19 downregulation confers erlotinib resistance through upregulation of PKM2 and phosphorylation of AKT in EGFR‐mutant lung cancers
  publication-title: Cancer Lett
– volume: 20
  start-page: 2767
  issue: 11
  year: 2019
  article-title: TGF‐β‐mediated epithelial‐mesenchymal transition and cancer metastasis
  publication-title: Int J Mol Sci
– volume: 34
  issue: 8
  year: 2020
  article-title: LncRNA H19 gene rs2839698 polymorphism is associated with a decreased risk of colorectal cancer in a Chinese Han population: a case‐control study
  publication-title: J Clin Lab Anal
– volume: 28
  start-page: 36984
  issue: 28
  year: 2021
  end-page: 37000
  article-title: MicroRNAs’ role in the environment‐related non‐communicable diseases and link to multidrug resistance, regulation, or alteration
  publication-title: Environ Sci Pollut Res
– volume: 28
  start-page: 812
  issue: 8
  year: 2014
  end-page: 828
  article-title: DNA methylation dynamics during epigenetic reprogramming in the germline and preimplantation embryos
  publication-title: Genes Dev
– volume: 11
  start-page: 6415
  year: 2018
  end-page: 6424
  article-title: LncRNA as a diagnostic and prognostic biomarker in bladder cancer: a systematic review and meta‐analysis
  publication-title: Onco Targets Ther
– volume: 24
  start-page: 5811
  issue: 10
  year: 2020
  end-page: 5816
  article-title: Inhibition of LncRNAH19 has the effect of anti‐tumour and enhancing sensitivity to gefitinib and chemotherapy in non‐small‐cell lung cancer in vivo
  publication-title: J Cell Mol Med
– volume: 23
  start-page: 6411
  issue: 9
  year: 2019
  end-page: 6428
  article-title: Long non‐coding RNA H19 is responsible for the progression of lung adenocarcinoma by mediating methylation‐dependent repression of CDH1 promoter
  publication-title: J Cell Mol Med
– volume: 28
  start-page: 491
  issue: 5
  year: 2014
  end-page: 501
  article-title: The H19 long noncoding RNA gives rise to microRNAs miR‐675‐3p and miR‐675‐5p to promote skeletal muscle differentiation and regeneration
  publication-title: Genes Dev
– volume: 12
  start-page: 4283
  year: 2020
  end-page: 4297
  article-title: Exosomal transfer of lncRNA H19 promotes erlotinib resistance in non‐small cell lung cancer via miR‐615‐3p/ATG7 axis
  publication-title: Cancer Manag Res
– volume: 20
  start-page: 511
  issue: 6
  year: 2023
  end-page: 522
  article-title: LncRNA polymorphisms and lung cancer risk
  publication-title: Personal Med
– volume: 14
  start-page: 860
  issue: 4
  year: 2018
  end-page: 863
  article-title: Expression level of long noncoding RNA H19 in plasma of patients with nonsmall cell lung cancer and its clinical significance
  publication-title: J Cancer Res Ther
– volume: 13
  start-page: 23
  year: 2022
  end-page: 36
  article-title: Curcumenol triggered ferroptosis in lung cancer cells via lncRNA H19/miR‐19b‐3p/FTH1 axis
  publication-title: Bioactive Mater
– volume: 101
  issue: 33
  year: 2022
  article-title: Role of noncoding RNAs and untranslated regions in cancer: a review
  publication-title: Medicine
– volume: 19
  start-page: 136
  issue: 1
  year: 2018
  article-title: Association between H19 SNP rs217727 and lung cancer risk in a Chinese population: a case control study
  publication-title: BMC Med Genet
– volume: 13
  start-page: 17
  issue: 1
  year: 2020
  end-page: 33
  article-title: Targeted therapy and checkpoint immunotherapy in lung cancer
  publication-title: Surg Pathol Clin
– volume: 14
  issue: 4
  year: 2021
  article-title: miRNA interplay: mechanisms and consequences in cancer
  publication-title: Dis Models Mech
– volume: 47
  start-page: 6357
  issue: 8
  year: 2020
  end-page: 6374
  article-title: An updated review of the H19 lncRNA in human cancer: molecular mechanism and diagnostic and therapeutic importance
  publication-title: Mol Biol Rep
– volume: 39
  start-page: 232
  issue: 1
  year: 2020
  article-title: TM4SF1 promotes EMT and cancer stemness via the Wnt/β‐catenin/SOX2 pathway in colorectal cancer
  publication-title: J Exp Clin Cancer Res
– volume: 184
  year: 2022
  article-title: Long non‐coding RNA (lncRNA) H19 in human cancer: from proliferation and metastasis to therapy
  publication-title: Pharmacol Res
– volume: 37
  start-page: 4007
  issue: 3
  year: 2016
  end-page: 4015
  article-title: c‐Myc‐regulated long non‐coding RNA H19 indicates a poor prognosis and affects cell proliferation in non‐small‐cell lung cancer
  publication-title: Tumor Biol
– volume: 13
  year: 2022
  article-title: The role of lncRNA H19 in tumorigenesis and drug resistance of human cancers
  publication-title: Front Genet
– volume: 36
  start-page: 1440
  issue: 4
  year: 2015
  end-page: 1452
  article-title: The interaction between MiR‐141 and lncRNA‐H19 in regulating cell proliferation and migration in gastric cancer
  publication-title: Cell Physiol Biochem
– volume: 500
  start-page: 253
  year: 2021
  end-page: 262
  article-title: The double‐edged sword of H19 lncRNA: insights into cancer therapy
  publication-title: Cancer Lett
– volume: 127
  start-page: 711
  issue: 5
  year: 2000
  end-page: 715
  article-title: Mechanisms of Igf2/H19 imprinting: DNA methylation, chromatin and long‐distance gene regulation
  publication-title: J Biochem
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  end-page: 249
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
– volume: 8
  start-page: 3932
  issue: 14
  year: 2018
  end-page: 3948
  article-title: Carcinoma‐associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19
  publication-title: Theranostics
– volume: 280
  start-page: 29625
  issue: 33
  year: 2005
  end-page: 29636
  article-title: H19 mRNA‐like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1
  publication-title: J Biol Chem
– volume: 12
  start-page: 4099
  year: 2019
  end-page: 4107
  article-title: Long non‐coding RNA H19 promotes the proliferation and invasion of lung cancer cells and regulates the expression of E‐cadherin, N‐cadherin, and vimentin
  publication-title: Onco Targets Ther
– volume: 10
  start-page: 9012
  issue: 8
  year: 2017
  end-page: 9020
  article-title: Upregulated lncRNA H19 promotes non‐small cell lung cancer cell proliferation through miR‐138/PDK1 axis
  publication-title: Int J Clin Exp Pathol
– volume: 42
  start-page: 937
  issue: 10
  year: 2022
  end-page: 970
  article-title: Non‐small cell lung cancer in China
  publication-title: Cancer Commun
– volume: 50
  start-page: 1801
  issue: 5
  year: 2017
  end-page: 1809
  article-title: H19 promotes the migration and invasion of colon cancer by sponging miR‐138 to upregulate the expression of HMGA1
  publication-title: Int J Oncol
– volume: 23
  start-page: 8309
  year: 2022
  article-title: LncRNA H19 impairs chemo and radiotherapy in tumorigenesis
  publication-title: Int J Mol Sci
– volume: 191
  year: 2023
  article-title: β‐Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR‐mutant non‐small cell lung cancer
  publication-title: Pharmacol Res
– volume: 1
  start-page: 49
  issue: 1
  year: 2002
  end-page: 52
  article-title: Focus on lung cancer
  publication-title: Cancer Cell
– volume: 23
  start-page: 10796
  issue: 24
  year: 2019
  end-page: 10802
  article-title: FOXF2 aggravates the progression of non‐small cell lung cancer through targeting lncRNA H19 to downregulate PTEN
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 120
  start-page: 18724
  issue: 11
  year: 2019
  end-page: 18735
  article-title: Upregulation of miR‐675‐5p induced by lncRNA H19 was associated with tumor progression and development by targeting tumor suppressor p53 in non‐small cell lung cancer
  publication-title: J Cell Biochem
– volume: 17
  start-page: 38
  issue: 1
  year: 2018
  article-title: Management of acquired resistance to EGFR TKI‐targeted therapy in advanced non‐small cell lung cancer
  publication-title: Mol Cancer
– volume: 6
  start-page: 942
  issue: 11
  year: 2020
  end-page: 950
  article-title: Targeting EMT in cancer with repurposed metabolic inhibitors
  publication-title: Trends Cancer
– volume: 1
  issue: 336
  year: 2023
  article-title: Molecular mechanism of lncRNAs in pathogenesis and diagnosis of auto‐immune diseases, with a special focus on lncRNA‐based therapeutic approaches
  publication-title: Life Sci
– volume: 14
  start-page: 184
  year: 2015
  article-title: The H19 long non‐coding RNA in cancer initiation, progression and metastasis—a proposed unifying theory
  publication-title: Mol Cancer
– volume: 2019
  start-page: 1
  year: 2019
  end-page: 11
  article-title: Potential role of lncRNA H19 as a cancer biomarker in human cancers detection and diagnosis: a pooled analysis based on 1585 subjects
  publication-title: BioMed Res Int
– volume: 37
  start-page: 278
  issue: 4
  year: 2019
  end-page: 285
  article-title: EGFR‐mutant adenocarcinomas that transform to small‐cell lung cancer and other neuroendocrine carcinomas: clinical outcomes
  publication-title: J Clin Oncol
– volume: 24
  issue: 22
  year: 2023
  article-title: Emerging role of circular RNAs in hepatocellular carcinoma immunotherapy
  publication-title: Int J Mol Sci
– volume: 222
  year: 2021
  article-title: LncRNA signature in colorectal cancer
  publication-title: Pathol Res Pract
– volume: 24
  start-page: 317
  issue: 8
  year: 2017
  end-page: 324
  article-title: Association of long non‐coding RNA H19 and microRNA‐21 expression with the biological features and prognosis of non‐small cell lung cancer
  publication-title: Cancer Gene Ther
– volume: 18
  start-page: 893
  issue: 1
  year: 2018
  article-title: Polymorphisms in the H19 gene and the risk of lung cancer among female never smokers in Shenyang, China
  publication-title: BMC Cancer
– volume: 22
  start-page: 316
  issue: 1
  year: 2022
  article-title: Notch‐associated lncRNAs profiling circuiting epigenetic modification in colorectal cancer
  publication-title: Cancer Cell Int
– volume: 15
  start-page: 4887
  issue: 7
  year: 2023
  end-page: 4901
  article-title: Progranulin modulates the progression of non‐small cell lung cancer through lncRNA H19
  publication-title: Am J Transl Res
– volume: 7
  start-page: 3748
  issue: 4
  year: 2016
  end-page: 3765
  article-title: The role of the oncofetal H19 lncRNA in tumor metastasis: orchestrating the EMT‐MET decision
  publication-title: Oncotarget
– volume: 31
  start-page: 44
  issue: 1
  year: 2020
  end-page: 54
  article-title: Long non‐coding RNA H19 confers resistance to gefitinib via miR‐148b‐3p/DDAH1 axis in lung adenocarcinoma
  publication-title: Anti‐Cancer Drugs
– volume: 7
  start-page: 25470
  issue: 18
  year: 2016
  end-page: 25477
  article-title: Association of genetic variants in lncRNA H19 with risk of colorectal cancer in a Chinese population
  publication-title: Oncotarget
– volume: 9
  start-page: 58
  issue: 5
  year: 2023
  article-title: The intergenic type LncRNA (LINC RNA) faces in cancer with in silico scope and a directed lens to LINC00511: a step toward ncRNA precision
  publication-title: Noncoding RNA
– volume: 509
  start-page: 81
  year: 2021
  end-page: 88
  article-title: LncRNA‐miRNA axes in breast cancer: novel points of interaction for strategic attack
  publication-title: Cancer Lett
– volume: 279
  start-page: 3159
  issue: 17
  year: 2012
  end-page: 3165
  article-title: Up‐regulated long non‐coding RNA H19 contributes to proliferation of gastric cancer cells
  publication-title: FEBS J
– volume: 40
  start-page: 3438
  issue: 6
  year: 2018
  end-page: 3446
  article-title: Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer
  publication-title: Oncol Rep
– volume: 26
  start-page: 30
  issue: 1
  year: 2020
  article-title: Long non‐coding RNA H19, a novel therapeutic target for pancreatic cancer
  publication-title: Mol Med
– volume: 238
  start-page: 1982
  issue: 9
  year: 2023
  end-page: 2009
  article-title: Decoding hepatocarcinogenesis from a noncoding RNAs perspective
  publication-title: J Cell Physiol
– volume: 22
  start-page: 5946
  issue: 18
  year: 2018
  end-page: 5953
  article-title: LncRNA H19 serves as a ceRNA and participates in non‐small cell lung cancer development by regulating microRNA‐107
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 11
  start-page: 2876
  issue: 8
  year: 2022
  end-page: 2886
  article-title: Hypoxia upregulates the expression of lncRNA H19 in non‐small cell lung cancer cells and induces drug resistance
  publication-title: Transl Cancer Res
– volume: 42
  start-page: 346
  issue: 7
  year: 2016
  end-page: 353
  article-title: Targeting H19 by lentivirus‐mediated RNA interference increases A549 cell migration and invasion
  publication-title: Exp Lung Res
– volume: 330
  year: 2023
  article-title: Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer
  publication-title: Life Sci
– volume: 133
  year: 2021
  article-title: EMT, cancer stem cells and autophagy; the three main axes of metastasis
  publication-title: Biomed Pharmacother
– volume: 9
  start-page: 95
  issue: 2
  year: 2009
  end-page: 107
  article-title: p53 polymorphisms: cancer implications
  publication-title: Nat Rev Cancer
– volume: 165
  year: 2023
  article-title: Molecular landscape of LncRNAs in bladder cancer: from drug resistance to novel LncRNA‐based therapeutic strategies
  publication-title: Biomed Pharmacother
– volume: 17
  start-page: 1372
  issue: 11
  year: 2018
  end-page: 1380
  article-title: LncRNA H19‐elevated LIN28B promotes lung cancer progression through sequestering miR‐196b
  publication-title: Cell Cycle
– volume: 48
  start-page: 1
  issue: 8
  year: 2021
  end-page: 15
  article-title: LncRNA as a multifunctional regulator in cancer multi‐drug resistance
  publication-title: Mol Biol Rep
– volume: 18
  start-page: 450
  issue: 2
  year: 2017
  article-title: The interplay of LncRNA‐H19 and its binding partners in physiological process and gastric carcinogenesis
  publication-title: Int J Mol Sci
– volume: 233
  start-page: 6768
  issue: 10
  year: 2018
  end-page: 6776
  article-title: H19 promotes non‐small‐cell lung cancer (NSCLC) development through STAT3 signaling via sponging miR‐17
  publication-title: J Cell Physiol
– volume: 9
  start-page: 1
  issue: 50
  year: 2019
  end-page: 13
  article-title: On the other side: manipulating the immune checkpoint landscape of dendritic cells to enhance cancer immunotherapy
  publication-title: Front Oncol
– volume: 18
  start-page: 155
  issue: 1
  year: 2019
  article-title: Novel immune checkpoint targets: moving beyond PD‐1 and CTLA‐4
  publication-title: Mol Cancer
– volume: 24
  start-page: 8178
  issue: 9
  year: 2023
  article-title: Endocan promotes Pro‐Tumorigenic signaling in lung cancer cells: modulation of cell proliferation, migration and lncRNAs H19 and HULC expression
  publication-title: Int J Mol Sci
– volume: 123
  year: 2020
  article-title: H19 lncRNA: roles in tumorigenesis
  publication-title: Biomed Pharmacother
– volume: 14
  start-page: 4486
  issue: 18
  year: 2022
  article-title: LncRNA H19 promotes lung adenocarcinoma progression via binding to mutant p53 R175H
  publication-title: Cancers
– volume: 27
  start-page: 167
  issue: 148
  year: 2019
  end-page: 170
  article-title: Molecular diagnostics and targeted therapies in non‐small cell lung cancer (NSCLC): an update
  publication-title: Discov Med
– volume: 65
  start-page: 625
  issue: 4
  year: 2021
  end-page: 639
  article-title: Non‐coding RNA in cancer
  publication-title: Essays Biochem
– volume: 59
  start-page: 90
  issue: 5
  year: 2021
  article-title: Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (review)
  publication-title: Int J Oncol
– volume: 376
  issue: 6589
  year: 2022
  article-title: Genome‐wide analysis of somatic noncoding mutation patterns in cancer
  publication-title: Science
– volume: 132
  issue: 11
  year: 2022
  article-title: Hypoxia‐inducible factors: cancer progression and clinical translation
  publication-title: J Clin Invest
– volume: 41
  start-page: 109
  issue: 2
  year: 2021
  end-page: 120
  article-title: LncRNA‐mediated posttranslational modifications and reprogramming of energy metabolism in cancer
  publication-title: Cancer Commun
– volume: 10
  start-page: 1715
  issue: 7
  year: 2021
  article-title: Hypoxia, metabolic reprogramming, and drug resistance in liver cancer
  publication-title: Cells
– volume: 21
  start-page: 644
  issue: 1
  year: 2021
  article-title: Silencing of the lncRNA H19 enhances sensitivity to X‐ray and carbon‐ions through the miR‐130a‐3p/WNK3 signaling axis in NSCLC cells
  publication-title: Cancer Cell Int
– volume: 27
  start-page: 1718
  issue: 10
  year: 2019
  end-page: 1725
  article-title: ncRNA‐encoded peptides or proteins and cancer
  publication-title: Mol Ther
– volume: 460
  start-page: 1
  issue: 1‐2
  year: 2019
  end-page: 8
  article-title: LncRNA H19 promotes lung cancer proliferation and metastasis by inhibiting miR‐200a function
  publication-title: Mol Cell Biochem
– volume: 102
  issue: 8
  year: 2023
  article-title: Non‐small cell lung cancer (NSCLC): a review of risk factors, diagnosis, and treatment
  publication-title: Medicine
– volume: 6
  start-page: 22513
  issue: 26
  year: 2015
  end-page: 22525
  article-title: The lncRNA H19 promotes epithelial to mesenchymal transition by functioning as miRNA sponges in colorectal cancer
  publication-title: Oncotarget
– volume: 37
  start-page: 5653
  issue: 4
  year: 2016
  article-title: Erratum to: c‐Myc‐regulated long non‐coding RNA H19 indicates a poor prognosis and affects cell proliferation in non‐small‐cell lung cancer
  publication-title: Tumor Biol
– volume: 40
  start-page: 436
  issue: 4
  year: 2022
  end-page: 447
  article-title: LncRNA H19 promoted the epithelial to mesenchymal transition and metastasis in gastric cancer via activating Wnt/β‐catenin signaling
  publication-title: Dig Dis
– volume: 29
  start-page: 212
  issue: 3
  year: 2019
  end-page: 226
  article-title: EMT transition states during tumor progression and metastasis
  publication-title: Trends Cell Biol
– ident: e_1_2_8_66_1
  doi: 10.1186/s12943-019-1091-2
– ident: e_1_2_8_67_1
  doi: 10.1016/j.bioactmat.2021.11.013
– ident: e_1_2_8_11_1
  doi: 10.1038/nrc2584
– volume: 10
  start-page: 9012
  issue: 8
  year: 2017
  ident: e_1_2_8_68_1
  article-title: Upregulated lncRNA H19 promotes non‐small cell lung cancer cell proliferation through miR‐138/PDK1 axis
  publication-title: Int J Clin Exp Pathol
– ident: e_1_2_8_14_1
  doi: 10.3390/ncrna9050058
– ident: e_1_2_8_5_1
  doi: 10.1097/MD.0000000000032899
– ident: e_1_2_8_46_1
  doi: 10.2147/OTT.S167853
– ident: e_1_2_8_7_1
  doi: 10.1172/JCI159839
– ident: e_1_2_8_20_1
  doi: 10.1007/s11356-021-14550-w
– ident: e_1_2_8_31_1
  doi: 10.1159/000430309
– ident: e_1_2_8_77_1
  doi: 10.1016/j.canlet.2020.05.009
– volume: 27
  start-page: 167
  issue: 148
  year: 2019
  ident: e_1_2_8_4_1
  article-title: Molecular diagnostics and targeted therapies in non‐small cell lung cancer (NSCLC): an update
  publication-title: Discov Med
– ident: e_1_2_8_27_1
  doi: 10.1016/j.prp.2021.153432
– ident: e_1_2_8_25_1
  doi: 10.1016/j.canlet.2021.04.002
– ident: e_1_2_8_3_1
  doi: 10.1016/S1535-6108(02)00027-2
– ident: e_1_2_8_60_1
  doi: 10.3390/ijms23158309
– ident: e_1_2_8_91_1
  doi: 10.1159/000518627
– ident: e_1_2_8_22_1
  doi: 10.3390/ijms242216484
– ident: e_1_2_8_87_1
  doi: 10.1016/j.tcb.2018.12.001
– volume: 9
  start-page: 1
  issue: 50
  year: 2019
  ident: e_1_2_8_92_1
  article-title: On the other side: manipulating the immune checkpoint landscape of dendritic cells to enhance cancer immunotherapy
  publication-title: Front Oncol
– ident: e_1_2_8_90_1
  doi: 10.7150/thno.25541
– ident: e_1_2_8_88_1
  doi: 10.3390/ijms20112767
– ident: e_1_2_8_29_1
  doi: 10.3389/fgene.2022.1005522
– ident: e_1_2_8_10_1
  doi: 10.1038/s41418-018-0246-9
– ident: e_1_2_8_32_1
  doi: 10.18632/oncotarget.6387
– volume: 1
  issue: 336
  year: 2023
  ident: e_1_2_8_21_1
  article-title: Molecular mechanism of lncRNAs in pathogenesis and diagnosis of auto‐immune diseases, with a special focus on lncRNA‐based therapeutic approaches
  publication-title: Life Sci
– volume: 2019
  start-page: 1
  year: 2019
  ident: e_1_2_8_50_1
  article-title: Potential role of lncRNA H19 as a cancer biomarker in human cancers detection and diagnosis: a pooled analysis based on 1585 subjects
  publication-title: BioMed Res Int
– ident: e_1_2_8_64_1
  doi: 10.1002/jcp.26530
– ident: e_1_2_8_49_1
  doi: 10.1016/j.biopha.2019.109774
– ident: e_1_2_8_79_1
  doi: 10.2147/CMAR.S241095
– ident: e_1_2_8_39_1
  doi: 10.1186/s10020-020-00156-4
– ident: e_1_2_8_72_1
  doi: 10.1080/01902148.2016.1223229
– ident: e_1_2_8_13_1
  doi: 10.1016/j.ymthe.2019.09.001
– ident: e_1_2_8_57_1
  doi: 10.3390/cancers14184486
– ident: e_1_2_8_93_1
  doi: 10.1111/jcmm.14533
– ident: e_1_2_8_23_1
  doi: 10.1002/cac2.12108
– ident: e_1_2_8_48_1
  doi: 10.1007/s13277-015-4347-5
– ident: e_1_2_8_53_1
  doi: 10.1007/s13277-015-4185-5
– ident: e_1_2_8_45_1
  doi: 10.3892/ijo.2017.3941
– volume: 40
  start-page: 3438
  issue: 6
  year: 2018
  ident: e_1_2_8_82_1
  article-title: Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer
  publication-title: Oncol Rep
– ident: e_1_2_8_26_1
  doi: 10.2217/pme-2023-0081
– ident: e_1_2_8_30_1
  doi: 10.18632/oncotarget.4154
– ident: e_1_2_8_47_1
  doi: 10.1002/jcb.29182
– ident: e_1_2_8_70_1
  doi: 10.2147/OTT.S185156
– ident: e_1_2_8_89_1
  doi: 10.1186/s13046-020-01690-z
– ident: e_1_2_8_16_1
  doi: 10.1002/jcp.31076
– ident: e_1_2_8_12_1
  doi: 10.1200/JCO.18.01585
– ident: e_1_2_8_59_1
  doi: 10.1016/j.path.2019.11.002
– ident: e_1_2_8_9_1
  doi: 10.1126/science.abg5601
– ident: e_1_2_8_35_1
  doi: 10.1101/gad.234294.113
– ident: e_1_2_8_41_1
  doi: 10.1186/s12943-015-0458-2
– ident: e_1_2_8_18_1
  doi: 10.1042/EBC20200032
– ident: e_1_2_8_40_1
  doi: 10.1007/s11033-020-05695-x
– ident: e_1_2_8_86_1
  doi: 10.1016/j.biopha.2020.110909
– ident: e_1_2_8_15_1
  doi: 10.1186/s12935-022-02736-2
– ident: e_1_2_8_19_1
  doi: 10.1242/dmm.047662
– ident: e_1_2_8_81_1
  doi: 10.1111/jcmm.15245
– ident: e_1_2_8_83_1
  doi: 10.18632/oncotarget.13708
– ident: e_1_2_8_38_1
  doi: 10.1097/MD.0000000000030045
– ident: e_1_2_8_17_1
  doi: 10.1016/j.biopha.2023.115242
– ident: e_1_2_8_6_1
  doi: 10.1016/j.cllc.2022.11.005
– volume: 15
  start-page: 4887
  issue: 7
  year: 2023
  ident: e_1_2_8_62_1
  article-title: Progranulin modulates the progression of non‐small cell lung cancer through lncRNA H19
  publication-title: Am J Transl Res
– ident: e_1_2_8_84_1
  doi: 10.21037/tcr-22-1812
– ident: e_1_2_8_56_1
  doi: 10.1186/s12885-018-4795-6
– volume: 23
  start-page: 10796
  issue: 24
  year: 2019
  ident: e_1_2_8_63_1
  article-title: FOXF2 aggravates the progression of non‐small cell lung cancer through targeting lncRNA H19 to downregulate PTEN
  publication-title: Eur Rev Med Pharmacol Sci
– ident: e_1_2_8_69_1
  doi: 10.1080/15384101.2018.1482137
– ident: e_1_2_8_55_1
  doi: 10.1186/s12881-018-0573-1
– ident: e_1_2_8_51_1
  doi: 10.4103/jcrt.JCRT_733_17
– ident: e_1_2_8_43_1
  doi: 10.1111/j.1742-4658.2012.08694.x
– ident: e_1_2_8_52_1
  doi: 10.1002/jcla.23311
– ident: e_1_2_8_42_1
  doi: 10.1016/j.canlet.2020.11.006
– ident: e_1_2_8_78_1
  doi: 10.1186/s12935-021-02268-1
– ident: e_1_2_8_33_1
  doi: 10.18632/oncotarget.8330
– ident: e_1_2_8_37_1
  doi: 10.1101/gad.234419.113
– ident: e_1_2_8_44_1
  doi: 10.1074/jbc.M504033200
– ident: e_1_2_8_24_1
  doi: 10.1016/j.phrs.2022.106418
– ident: e_1_2_8_36_1
  doi: 10.3390/ijms18020450
– ident: e_1_2_8_74_1
  doi: 10.3892/ijo.2021.5270
– ident: e_1_2_8_80_1
  doi: 10.1097/CAD.0000000000000831
– ident: e_1_2_8_8_1
  doi: 10.3390/cells10071715
– ident: e_1_2_8_65_1
  doi: 10.3390/ijms24098178
– volume: 22
  start-page: 5946
  issue: 18
  year: 2018
  ident: e_1_2_8_73_1
  article-title: LncRNA H19 serves as a ceRNA and participates in non‐small cell lung cancer development by regulating microRNA‐107
  publication-title: Eur Rev Med Pharmacol Sci
– ident: e_1_2_8_85_1
  doi: 10.1016/j.trecan.2020.06.005
– ident: e_1_2_8_71_1
  doi: 10.2147/OTT.S245710
– ident: e_1_2_8_28_1
  doi: 10.1007/s11033-021-06603-7
– ident: e_1_2_8_94_1
  doi: 10.1016/j.lfs.2023.121997
– ident: e_1_2_8_61_1
  doi: 10.1007/s11010-019-03564-1
– ident: e_1_2_8_75_1
  doi: 10.1186/s12943-018-0777-1
– ident: e_1_2_8_34_1
  doi: 10.1093/oxfordjournals.jbchem.a022661
– ident: e_1_2_8_76_1
  doi: 10.1016/j.phrs.2023.106739
– ident: e_1_2_8_58_1
  doi: 10.1002/cac2.12359
– ident: e_1_2_8_2_1
  doi: 10.3322/caac.21660
– ident: e_1_2_8_54_1
  doi: 10.1038/cgt.2017.20
SSID ssj0009630
Score 2.3800023
SecondaryResourceType review_article
Snippet Lung cancer holds the position of being the primary cause of cancer‐related fatalities on a global scale. Furthermore, it exhibits the highest mortality rate...
Lung cancer holds the position of being the primary cause of cancer-related fatalities on a global scale. Furthermore, it exhibits the highest mortality rate...
SourceID proquest
pubmed
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e4072
SubjectTerms Carcinoma, Non-Small-Cell Lung - diagnosis
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Cell migration
Disease resistance
EMT
Epithelial-Mesenchymal Transition
Gene Expression Regulation, Neoplastic
Humans
lncRNA H19
Lung cancer
Lung diseases
Lung Neoplasms - diagnosis
Lung Neoplasms - genetics
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Metastases
metastasis
Molecular modelling
Non-coding RNA
RNA, Long Noncoding - genetics
RNA, Long Noncoding - metabolism
Survival
therapy resistance
Tumorigenesis
Title Emerging roles of long noncoding RNA H19 in human lung cancer
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcbf.4072
https://www.ncbi.nlm.nih.gov/pubmed/39031589
https://www.proquest.com/docview/3072377165
https://www.proquest.com/docview/3082958094
Volume 42
WOSCitedRecordID wos001251336200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVWIB
  databaseName: Wiley Online Library Full Collection 2020
  customDbUrl:
  eissn: 1099-0844
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0009630
  issn: 0263-6484
  databaseCode: DRFUL
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://onlinelibrary.wiley.com
  providerName: Wiley-Blackwell
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8NAEB5sq-iLR73qUVYQfYptNsdmH2u19KEUKRb6FjbbDRRKIq0K_ntncrSICoJPIckku8yxM7PHNwDXgZn6U4FpSYTO0HJ5rCwlIwKCFNrlthJRDpI0EMNhMJnIp2JXJZ2FyfEhVhNuZBnZeE0GrqJlaw0aqqP4jtC9KlDjqLZeFWoPo954sIbc9Z1ihsWxfDdwS-jZNm-V3351Rt8izK8Ba-Zxenv_6es-7BZxJuvkinEAGyapw1ZeefKjDtvdstDbIWQTU1SriNFWwyVLYzZP8S5JE52Sa2OjYYf1bclmCctq-rE5DhFMk8IsjmDce3zu9q2iqoKlCYkQhWKrQBihMRCJMAH28QHmfVq3YzosYmKFHl7HXGmN9u4q34gYo5apH9taarftHEMVO2BOgUmkVQ6PHK4UBn4oY0-6U2VL42nhtlUDbkv2hrqAHKfKF_MwB0vmITImJMY04GpF-ZLDbPxAc1FKKCwMbRniEMUdgUmfh79YvUYG0rqHSkz6RjQBl16AiWwDTnLJrhpxJJW5CGQDbjIB_tp62L3v0fXsr4TnsMMxAMq3lV1A9XXxZi5hU7-_zpaLJlTEJGgWKvsJqYTpyA
linkProvider Wiley-Blackwell
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1ZS8NAEB48qS8e9arnCqJPsc1mm83iU62WirWIKPgWNtsNFEoirQr-e2dyVEQFwaeQZJJd5tg5svkG4DiwA38gMS2J0Bk6gsfa0SoiIEhpBHe1jHKQpJ7s94OnJ3U3A-flvzA5PsS04EaWka3XZOBUkK5_ooaaKD4jeK9ZmBeoRaje85f3ncfeJ-au7xUlFs_xRSBK7NkGr5fPfvVG30LMrxFr5nI6K_-a7CosF5Ema-WqsQYzNqnCYt578r0KlXbZ6m0dstIUdStitNlwwtKYjVI8S9LEpOTc2H2_xbquYsOEZV392AgXCWZIZcYb8Ni5emh3naKvgmMIixDF4upAWmkwFIkwBfbxAmZ-xjRi-l3Exhp9vIm5NgYtXmjfyhjjloEfu0YZ0fA2YQ4nYLeBKaTVHo88rjWGfijlphID7SrbNFI0dA1OS_6GpgAdp94XozCHS-YhMiYkxtTgaEr5nANt_ECzV4ooLExtEuIixT2JaV8TXzG9jQykLx86sekr0QRcNQNMZWuwlYt2OoinqNFFoGpwkknw19HD9kWHjjt_JTyESvfhthf2rvs3u7DEMRzKN5ntwdzL-NXuw4J5exlOxgeF5n4AMyns0A
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-VFgYvA7YBhQJGQuwpa-O4cSyeupZoiKqaJir1LXIcW5pUJVU_kPbf7y4frSZAQuIpSnKJrTuf785xfj-Az5HNwkxiWZJiMPQEd9rTKiUgSGkE97VMK5CkqZzNosVCXbfga_MvTIUPsV9wI88o52tycLvKXP-AGmpSd0HwXo-gI4hDpg2dyU08nx4wd8OgXmIJvFBEosGeHfB-8-zDaPRbivkwYy1DTvz8vzr7Ao7rTJONqqHxElo2P4EnFffk3Qk8HTdUb6dQLk0RWxGjzYYbVji2LPAsL3JTUHBjN7MRu_IVu81ZyerHljhJMENDZn0G8_jbz_GVV_MqeIawCNEsvo6klQZTkRRL4BAvYOVnzMDR7yLWaYzxxnFtDHq80KGVDvOWLHS-UUYMglfQxg7YN8AUyuqApwHXGlM_tPJQiUz7yg6NFAPdhfNGv4mpQceJ-2KZVHDJPEHFJKSYLnzaS64qoI0_yPQaEyW1q20SnKR4ILHsG-Ir9rdRgfTlQ-e22JFMxNUwwlK2C68r0-4bCRQRXUSqC19KC_619WR8GdPx7b8KfoSj60mcTL_PfryDZxyzoWqPWQ_a2_XOvofH5tf2drP-UA_ce9kA7Es
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Emerging+roles+of+long+noncoding+RNA+H19+in+human+lung+cancer&rft.jtitle=Cell+biochemistry+and+function&rft.au=Ahmad%2C+Irfan&rft.au=Jasim%2C+Saade+Abdalkareem&rft.au=Sergeevna%2C+Klunko+Nataliya&rft.au=Jyothi+S%2C+Renuka&rft.date=2024-06-01&rft.issn=1099-0844&rft.eissn=1099-0844&rft.volume=42&rft.issue=4&rft.spage=e4072&rft_id=info:doi/10.1002%2Fcbf.4072&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0263-6484&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0263-6484&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0263-6484&client=summon